139 related articles for article (PubMed ID: 25438755)
1. Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
Ishihara T; Koga Y; Mori K; Sugasawa K; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2014 Nov; 22(22):6324-32. PubMed ID: 25438755
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.
Ishihara T; Koga Y; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2015 Jan; 23(2):277-89. PubMed ID: 25523211
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
6. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
7. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
8. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
9. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in vivo antithrombotic evaluation and molecular docking.
Amin KM; Abdel Gawad NM; Abdel Rahman DE; El Ashry MK
Bioorg Chem; 2014 Feb; 52():31-43. PubMed ID: 24316885
[TBL] [Abstract][Full Text] [Related]
10. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa.
Thakur R; Kumar A; Bose B; Panda D; Saikia D; Chattopadhyay P; Mukherjee AK
Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.
de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C
J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612
[TBL] [Abstract][Full Text] [Related]
12. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Hashimoto T; Suzuki K; Kihara Y; Iwatsubo T; Miyashita A; Heeringa M; Onkels H; Groenendaal D; Verheggen F; van Marle S; Usui T
Xenobiotica; 2013 Jun; 43(6):534-47. PubMed ID: 23167531
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
14. β-D-glucosyl conjugates of highly potent inhibitors of blood coagulation factor Xa bearing 2-chorothiophene as a P1 motif.
Lopopolo G; de Candia M; Panza L; Romano MR; Lograno MD; Campagna F; Altomare C
ChemMedChem; 2012 Sep; 7(9):1669-77. PubMed ID: 22851501
[TBL] [Abstract][Full Text] [Related]
15. The role of structural information in the discovery of direct thrombin and factor Xa inhibitors.
Nar H
Trends Pharmacol Sci; 2012 May; 33(5):279-88. PubMed ID: 22503439
[TBL] [Abstract][Full Text] [Related]
16. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
17. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H
Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438
[TBL] [Abstract][Full Text] [Related]
18. N(2)-Aroylanthranilamide inhibitors of human factor Xa.
Yee YK; Tebbe AL; Linebarger JH; Beight DW; Craft TJ; Gifford-Moore D; Goodson T; Herron DK; Klimkowski VJ; Kyle JA; Sawyer JS; Smith GF; Tinsley JM; Towner RD; Weir L; Wiley MR
J Med Chem; 2000 Mar; 43(5):873-82. PubMed ID: 10715154
[TBL] [Abstract][Full Text] [Related]
19. Microfluidic Chip-Based Online Screening Coupled to Mass Spectrometry: Identification of Inhibitors of Thrombin and Factor Xa.
Iyer JK; Otvos RA; Kool J; Kini RM
J Biomol Screen; 2016 Feb; 21(2):212-20. PubMed ID: 26323281
[TBL] [Abstract][Full Text] [Related]
20. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
